Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Clinical Trial, Phase II

Research Support, Non-U.S. Gov't

Clinical Trial

Randomized Controlled Trial

Clinical Trial, Phase I

Observational Study

Research Support, N.I.H., Extramural

Multicenter Study

Publication Year

From

Quick links

Individual year

2021

2018

2017

2013

2010

2005

2003

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Orotate Phosphoribosyltransferase""[mesh_terms]

9 Results

Searching titles within these results

QM/MM reveals the sequence of substrate binding during OPRT action.

Parag A Deshpande, N N Subrahmanyeswara Rao

Computational biology and chemistry 2018;74():31-38

Full Text

Abstract

Pyrophosphate interactions at the transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases.

Vern L Schramm, Yong Zhang

Journal of the American Chemical Society 2010;132(25):8787-94

Free Full Text

Abstract

Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.

Zi-Xian Wang, Feng-Hua Wang, Ming-Ming He, Dong-Sheng Zhang, Feng Wang, Yi-Xin Zeng, Shu-Qiang Yuan, Zhi-Qiang Wang, Hui-Yan Luo, Chao Ren, Miao-Zhen Qiu, Ying Jin, De-Shen Wang, Dong-Liang Chen, Zhao-Lei Zeng, Yu-Hong Li, Yang-Yang He, Yuan-Tao Hao, Pi Guo, Rui-Hua Xu

Cancer chemotherapy and pharmacology 2017;79(1):69-79

Free Full Text

Abstract

Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.

Keiji Koda, Hideaki Miyauchi, Chihiro Kosugi, Takashi Kaiho, Nobuhiro Takiguchi, Susumu Kobayashi, Takashi Maruyama, Hisahiro Matsubara

Anticancer research 2017;36(10):5325-5331

Full Text

Abstract

Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study).

Takeo Mori, Masayuki Ohue, Yasumasa Takii, Tadashi Hashizume, Tomoyuki Kato, Kenjiro Kotake, Toshihiko Sato, Toshiro Tango

Oncology reports 2013;29(2):437-44

Full Text

Abstract

A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis.

Sun Young Kim, Ji Yeon Baek, Jae Hwan Oh, Sung Chan Park, Dae Kyung Sohn, Min Ju Kim, Hee Jin Chang, Sun-Young Kong, Dae Yong Kim

Radiation oncology (London, England) 2017;12(1):62

Free Full Text

Abstract

Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

W Ichikawa, H Uetake, Y Shirota, H Yamada, T Takahashi, Z Nihei, K Sugihara, Y Sasaki, R Hirayama

British journal of cancer 2003;89(8):1486-92

Free Full Text

Abstract

Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.

Quincy Siu-Chung Chu, Lisa A Hammond, Garry Schwartz, Leonel Ochoa, Sun-Young Rha, Louis Denis, Kathleen Molpus, Brian Roedig, Stephen P Letrent, Bharat Damle, Arthur P DeCillis, Eric K Rowinsky

Clinical cancer research : an official journal of the American Association for Cancer Research 2005;10(15):4913-21

Full Text

Abstract

A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.

María A Lavanderos, Luis A Quiñones, Marcelo Garrido, Ricardo Armisén, Alejandro H Corvalán, Zhiguang Li, Yuwei Liao, Maria Rodriguez-Fernandez, Gareth I Owen, Juan Francisco Miquel, Ignacio N Retamal, Mauricio P Pinto, Matías Muñoz-Medel, Charlotte N Hill, Elisa Cumsille, María Loreto Bravo, Miguel Cordova-Delgado

BMC cancer 2021;21(1):1030

Free Full Text

Abstract

Results: 1 – 9 / 9

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Orotate Phosphoribosyltransferase""[mesh_terms]

QM/MM reveals the sequence of substrate binding during OPRT action.

Pyrophosphate interactions at the transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases.

Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.

Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.

Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study).

A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis.

Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.

A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.

Results for
""Orotate Phosphoribosyltransferase""[mesh_terms]